NAS10029,447+1.73%S&P7,638+1.14%GOLD$4,412+0.27%BTC$77,965+2.04%VIX15.48+0.26%live tape · as of 17:00 UTC
The Screen · Healthcare · Diagnostics & Research
Labcorp
LH · a US exchange · USD · Market cap $26.0B · 71,000 employees
Labcorp Holdings Inc.
FAIL · Does not pass the screen
321.10 USD
At the last full screen 2026-09-09
Screened 2026-09-09 · the tape above runs as of 17:00 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
The Label · The Season, Not the Day
This name holds its markup label.
Labcorp holds its Markup at $321.10. Consolidating, no directional conviction, held for 1 days.
As held on the ledger · 2026-09-09
Phase
Markup
Quantitative state
Consolidating, no directional conviction, held for 1 days
Price at the screen
$321.10
Valuation
26.58 trailing · 16.20 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.85
The Workings
Five Screens, Shown in Full
Does not pass. Debt ratio
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
35.48%
Below 33%
Interest-bearing debt is 35.5% of its assets, above the one-third ceiling the screen allows.
Fail
Interest-bearing cash
0.84%
Below 33%
Cash held in interest-bearing accounts and securities is 0.8% of assets, under the one-third limit.
Pass
Receivables
14.33%
Below 49%
Money owed to the company is 14.3% of assets, under the 49% limit.
Pass
Revenue purity
0.00%
Below 5%
Only 0.0% of revenue comes from non-compliant sources, under the 5% line.
Pass
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
What the Numbers Say It Is Worth
The Fair Value Range
Our framework reads AVOID: it trades at roughly a 20% discount to our $385.00 fair value, narrow competitive moat, 5.80% revenue growth.
Fair value range in USD, drawn from the 2026-09-09 screen. The gold marker is the market price at the same screen. A 19.9% margin of safety to the base estimate.
Third-party analyst targets: 16 covering, consensus Buy. The average target sits +9% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-09-09 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Routine blood tests mask rising debt risks
Think of Labcorp as the quiet lab behind every GP visit and hospital ward, running the tests that decide treatments. The business delivers steady 6% revenue growth and a 7% profit margin, yet it fails our ethical screen on debt levels.
We pass for that reason alone. A narrow moat, 11% ROE and forward earnings at 14.6 times do not offset the leverage issue, even with a reported 20% gap to our $340 fair value. Analyst chatter around a $320 target changes nothing.
The real concern is whether current margins hold if interest costs climb or volumes soften. Cyclical healthcare spending offers little cushion. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
LH trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 7.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310.
2026-08-04Markup · changed$314.23+18.5%Entry 4
The framework has shifted from markdown to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 18.5% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows excellent risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310.
2026-07-18Markdown$265.15+0.0%Entry 3
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 4%. Our forward projection puts the odds of a 10% gain over the next month near 16%. The street (17 analysts) rates it buy, with a mean price target of $310.
2026-07-03Markdown$265.15+0.0%Entry 2
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Markdown$265.15Entry 1
The framework reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
